380 related articles for article (PubMed ID: 25460020)
41. [The approaches in the discovery of antidepressants using affective disorder models].
Saitoh A; Yamaguchi K; Murasawa H; Kamei J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):75-82. PubMed ID: 12762219
[TBL] [Abstract][Full Text] [Related]
42. Antidepressant-like effects of buprenorphine in rats are strain dependent.
Browne CA; van Nest DS; Lucki I
Behav Brain Res; 2015 Feb; 278():385-92. PubMed ID: 25453747
[TBL] [Abstract][Full Text] [Related]
43. Emerging drugs for major depressive disorder.
Connolly KR; Thase ME
Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
[TBL] [Abstract][Full Text] [Related]
44. Role of Neuro-Immunological Factors in the Pathophysiology of Mood Disorders: Implications for Novel Therapeutics for Treatment Resistant Depression.
Bhattacharya A; Drevets WC
Curr Top Behav Neurosci; 2017; 31():339-356. PubMed ID: 27677784
[TBL] [Abstract][Full Text] [Related]
45. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study.
Bares M; Novak T; Kopecek M; Stopkova P; Cermak J; Kozeny J; Höschl C
Int J Psychiatry Clin Pract; 2013 Feb; 17(1):35-43. PubMed ID: 22486580
[TBL] [Abstract][Full Text] [Related]
46. Rodent models of depression: reexamining validity without anthropomorphic inference.
Holmes PV
Crit Rev Neurobiol; 2003; 15(2):143-74. PubMed ID: 14977368
[TBL] [Abstract][Full Text] [Related]
47. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.
Bhagwagar Z; Torbeyns A; Hennicken D; Zheng M; Dunlop BW; Mathew SJ; Khan A; Weisler R; Nelson C; Shelton R; Thase ME; Lane R
J Clin Psychopharmacol; 2015 Aug; 35(4):454-9. PubMed ID: 25961781
[TBL] [Abstract][Full Text] [Related]
48. Animal models of major depressive disorder and the implications for drug discovery and development.
Demin KA; Sysoev M; Chernysh MV; Savva AK; Koshiba M; Wappler-Guzzetta EA; Song C; De Abreu MS; Leonard B; Parker MO; Harvey BH; Tian L; Vasar E; Strekalova T; Amstislavskaya TG; Volgin AD; Alpyshov ET; Wang D; Kalueff AV
Expert Opin Drug Discov; 2019 Apr; 14(4):365-378. PubMed ID: 30793996
[TBL] [Abstract][Full Text] [Related]
49. [Folates in the treatment of depression].
Erbe S; Pellert UN
Fortschr Neurol Psychiatr; 2014 Feb; 82(2):78-83. PubMed ID: 24519190
[TBL] [Abstract][Full Text] [Related]
50. The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives.
Fabbri C; Corponi F; Souery D; Kasper S; Montgomery S; Zohar J; Rujescu D; Mendlewicz J; Serretti A
Int J Neuropsychopharmacol; 2019 Feb; 22(2):93-104. PubMed ID: 29688548
[TBL] [Abstract][Full Text] [Related]
51. Animal inflammation-based models of depression and their application to drug discovery.
Ma L; Demin KA; Kolesnikova TO; Khatsko SL; Zhu X; Yuan X; Song C; Meshalkina DA; Leonard BE; Tian L; Kalueff AV
Expert Opin Drug Discov; 2017 Oct; 12(10):995-1009. PubMed ID: 28816544
[TBL] [Abstract][Full Text] [Related]
52. Effects of chronic bryostatin-1 on treatment-resistant depression in rats.
Alkon DL; Hongpaisan J; Sun MK
Eur J Pharmacol; 2017 Jul; 807():71-74. PubMed ID: 28472666
[TBL] [Abstract][Full Text] [Related]
53. The future of rodent models in depression research.
Gururajan A; Reif A; Cryan JF; Slattery DA
Nat Rev Neurosci; 2019 Nov; 20(11):686-701. PubMed ID: 31578460
[TBL] [Abstract][Full Text] [Related]
54. The endocannabinoid/endovanilloid system and depression.
Smaga I; Bystrowska B; Gawliński D; Przegaliński E; Filip M
Curr Neuropharmacol; 2014 Sep; 12(5):462-74. PubMed ID: 25426013
[TBL] [Abstract][Full Text] [Related]
55. Treatment-resistant Late-life Depression: Challenges and Perspectives.
Knöchel C; Alves G; Friedrichs B; Schneider B; Schmidt-Rechau A; Wenzler S; Schneider A; Prvulovic D; Carvalho AF; Oertel-Knöchel V
Curr Neuropharmacol; 2015; 13(5):577-91. PubMed ID: 26467408
[TBL] [Abstract][Full Text] [Related]
56. Treatment-resistant depression - recommendations of the National Consultant in the field of psychiatry.
Gałecki P; Bliźniewska-Kowalska K
Psychiatr Pol; 2021 Feb; 55(1):7-21. PubMed ID: 34021543
[TBL] [Abstract][Full Text] [Related]
57. Using rodents to model abnormal sensitivity to feedback in depression.
Rygula R; Noworyta-Sokolowska K; Drozd R; Kozub A
Neurosci Biobehav Rev; 2018 Dec; 95():336-346. PubMed ID: 30347197
[TBL] [Abstract][Full Text] [Related]
58. The pharmacological management of treatment-resistant depression: what does the future hold?
Serretti A
Expert Opin Pharmacother; 2023; 24(18):1923-1925. PubMed ID: 37995141
[No Abstract] [Full Text] [Related]
59. An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders.
Barajaz AM; Kliethermes CL
Drug Alcohol Depend; 2017 Dec; 181():77-84. PubMed ID: 29035708
[TBL] [Abstract][Full Text] [Related]
60. Advancing preclinical chronic stress models to promote therapeutic discovery for human stress disorders.
Gyles TM; Nestler EJ; Parise EM
Neuropsychopharmacology; 2024 Jan; 49(1):215-226. PubMed ID: 37349475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
